journal article·2023-12Open access

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

Fangyuan Li, Junxian Yu, Tao Pan, Haoran Feng, Jianfang Li, Beiqin Yu, Zhiyuan Fan, Qingqing Sang, Mengdi Chen, Mingde Zang, Junyi Hou, Xiongyan Wu, Yingyan Yu, Yuan‐Yuan Li, Chao Yan, Zhenggang Zhu, Liping Su, Bingya Liu

Advanced Science· Volume 10· Issue 34

Abstract

Abstract Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low among patients with gastric cancer (GC). The findings of this study illustrated that the overexpression of bromodomain PHD finger transcription factor (BPTF) is partially responsible for erlotinib resistance in GC, and the combination of the BPTF inhibitor AU‐1 with erlotinib synergistically inhibited tumor growth both in vivo and in vitro. AU‐1 inhibited the epigenetic function of BPTF and decreased the transcriptional activity of c‐MYC on PLCG1 by attenuating chromosome accessibility of the PLCG1 promoter region, thus decreasing the expression of p‐PLCG1 and p‐Erk and eventually improving the sensitivity of GC cells to erlotinib. In patient‐derived xenograft (PDX) models, AU‐1 monotherapy exhibited remarkable tumor‐inhibiting activity and is synergistic anti‐tumor effects when combined with erlotinib. Altogether, the findings illustrate that BPTF affects the responsiveness of GC to erlotinib by epigenetically regulating the c‐MYC/PLCG1/pErk axis, and the combination of BPTF inhibitors and erlotinib is a viable therapeutic approach for GC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · Cancer-related gene regulation · Chromatin Remodeling and Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery Shanghai Key Laboratory of Gastric Neoplasms Shanghai Institute of Digestive Surgery Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200025 P. R. China

Department of Gastric Cancer Surgery Fudan University Shanghai Cancer Center Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China

Shanghai Center for Bioinformation Technology Shanghai Engineering Research Center of Pharmaceutical Translation & Shanghai Industrial Technology Institute Shanghai 202163 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shanghai Municipality

References (87)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1016/S0140-6736(16)30354-310.1016/S0140-6736(16)30354-3 ↗
3. 10.18632/oncotarget.1482510.18632/oncotarget.14825 ↗
4. 10.1177/101042831771462610.1177/1010428317714626 ↗
5. 10.1111/apm.1235910.1111/apm.12359 ↗
6. 10.2147/CMAR.S14961910.2147/CMAR.S149619 ↗
7. 10.1136/esmoopen-2016-00008810.1136/esmoopen-2016-000088 ↗
8. 10.1002/1878-0261.1215510.1002/1878-0261.12155 ↗
9. 10.1093/annonc/mdm22210.1093/annonc/mdm222 ↗
10. 10.1056/NEJMra070770410.1056/NEJMra0707704 ↗
11. 10.1677/erc.0.010000110.1677/erc.0.0100001 ↗
12. 10.1007/s00268-007-9016-410.1007/s00268-007-9016-4 ↗
13. 10.1016/1040-8428(94)00144-I10.1016/1040-8428(94)00144-I ↗
14. 10.1111/j.1365-2559.2008.03021.x10.1111/j.1365-2559.2008.03021.x ↗
15. 10.1158/1078-0432.CCR-08-106410.1158/1078-0432.CCR-08-1064 ↗
16. 10.1016/S0093-7754(03)70010-410.1016/S0093-7754(03)70010-4 ↗
17. 10.1016/j.lungcan.2013.11.02310.1016/j.lungcan.2013.11.023 ↗
18. 10.1186/s12885-018-4108-010.1186/s12885-018-4108-0 ↗
19. 10.1158/1078-0432.CCR-12-131810.1158/1078-0432.CCR-12-1318 ↗
20. 10.1093/jnci/92.3.20510.1093/jnci/92.3.205 ↗
21. 10.1200/JCO.2006.07.131610.1200/JCO.2006.07.1316 ↗
22. 10.1016/j.apsb.2015.07.00110.1016/j.apsb.2015.07.001 ↗
23. 10.1093/nar/gks111110.1093/nar/gks1111 ↗
24. 10.1016/j.cell.2016.06.01710.1016/j.cell.2016.06.017 ↗
25. 10.1038/s41586-019-1186-310.1038/s41586-019-1186-3 ↗
26. 10.1038/nature1100310.1038/nature11003 ↗
27. 10.1038/s41586-019-1103-910.1038/s41586-019-1103-9 ↗
28. 10.1016/S0092-8674(00)80797-710.1016/S0092-8674(00)80797-7 ↗
29. 10.1016/S1097-2765(01)00345-810.1016/S1097-2765(01)00345-8 ↗
30. 10.1101/gad.62181110.1101/gad.621811 ↗
31. 10.1016/j.febslet.2011.09.00310.1016/j.febslet.2011.09.003 ↗
32. 10.1039/C8OB02599A10.1039/C8OB02599A ↗
33. 10.1021/acschembio.5b0048310.1021/acschembio.5b00483 ↗
34. 10.1371/journal.pone.011172810.1371/journal.pone.0111728 ↗
35. 10.1038/nprot.2013.15010.1038/nprot.2013.150 ↗
36. 10.1093/nar/gkp33510.1093/nar/gkp335 ↗
37. 10.1016/j.ctrv.2012.09.00710.1016/j.ctrv.2012.09.007 ↗
38. 10.1016/j.ejca.2012.12.01610.1016/j.ejca.2012.12.016 ↗
39. 10.1007/s10120-018-0806-110.1007/s10120-018-0806-1 ↗
40. 10.1016/S0140-6736(13)61719-510.1016/S0140-6736(13)61719-5 ↗
41. 10.1016/S2468-1253(21)00313-710.1016/S2468-1253(21)00313-7 ↗
42. 10.2217/fon.14.10610.2217/fon.14.106 ↗
43. 10.1136/gutjnl-2011-30183910.1136/gutjnl-2011-301839 ↗
44. 10.1200/JCO.2001.19.13.326710.1200/JCO.2001.19.13.3267 ↗
45. 10.1200/JCO.2004.06.07510.1200/JCO.2004.06.075 ↗
46. 10.1038/bjc.2016.45610.1038/bjc.2016.456 ↗
47. 10.1111/j.1525-1438.2005.00137.x10.1111/j.1525-1438.2005.00137.x ↗
48. 10.1002/cncr.2288610.1002/cncr.22886 ↗
49. Ko A. · Biologics. · 2008 · 2 · 83
50. 10.1016/j.ygyno.2012.06.02810.1016/j.ygyno.2012.06.028 ↗
51. 10.18632/oncotarget.530210.18632/oncotarget.5302 ↗
52. Dai M. · Am. J. Transl. Res. · 2019 · 11 · 7398
53. 10.18632/aging.10152010.18632/aging.101520 ↗
54. 10.1038/s41467-019-11020-310.1038/s41467-019-11020-3 ↗
55. 10.1007/s00432-015-1937-y10.1007/s00432-015-1937-y ↗
56. 10.1038/s41388-019-1125-710.1038/s41388-019-1125-7 ↗
57. Pan Y. · Oncol. Rep. · 2019 · 41 · 246
58. 10.1139/bcb-2020-022710.1139/bcb-2020-0227 ↗
59. 10.1093/jnci/djv03410.1093/jnci/djv034 ↗
60. 10.1016/j.stemcr.2018.01.02010.1016/j.stemcr.2018.01.020 ↗
61. 10.1016/j.stemcr.2017.04.03110.1016/j.stemcr.2017.04.031 ↗
62. 10.1016/j.ajhg.2017.08.01410.1016/j.ajhg.2017.08.014 ↗
63. 10.1158/0008-5472.CAN-15-312510.1158/0008-5472.CAN-15-3125 ↗
64. 10.18632/oncotarget.1783410.18632/oncotarget.17834 ↗
65. Carabet L. A. · Int. J. Mol. Sci. · 2018 · 20
66. 10.3389/fcell.2017.0001010.3389/fcell.2017.00010 ↗
67. 10.1016/0092-8674(91)90461-710.1016/0092-8674(91)90461-7 ↗
68. 10.1016/j.cell.2010.06.01110.1016/j.cell.2010.06.011 ↗
69. 10.1186/1478-811X-10-2710.1186/1478-811X-10-27 ↗
70. 10.1016/0092-8674(94)90160-010.1016/0092-8674(94)90160-0 ↗
71. 10.1146/annurev.biochem.70.1.28110.1146/annurev.biochem.70.1.281 ↗
72. 10.5603/FHC.2014.002110.5603/FHC.2014.0021 ↗
73. 10.18632/oncotarget.697610.18632/oncotarget.6976 ↗
74. 10.1016/j.bbrc.2011.09.12110.1016/j.bbrc.2011.09.121 ↗
75. 10.1016/j.ebiom.2023.10445110.1016/j.ebiom.2023.104451 ↗
76. 10.1146/annurev-physiol-021909-13591710.1146/annurev-physiol-021909-135917 ↗
77. 10.1016/j.cell.2007.12.01410.1016/j.cell.2007.12.014 ↗
78. 10.1016/j.ccr.2010.03.01810.1016/j.ccr.2010.03.018 ↗
79. 10.1038/nature1112510.1038/nature11125 ↗
80. 10.1016/j.ccr.2010.05.02610.1016/j.ccr.2010.05.026 ↗
81. 10.1186/gb-2007-8-2-r2410.1186/gb-2007-8-2-r24 ↗
82. 10.1093/bioinformatics/btr06410.1093/bioinformatics/btr064 ↗
83. 10.1093/bioinformatics/btp12010.1093/bioinformatics/btp120 ↗
84. 10.1186/1471-2105-12-32310.1186/1471-2105-12-323 ↗
85. 10.1093/nar/gkr48310.1093/nar/gkr483 ↗
86. 10.1038/mt.2016.710.1038/mt.2016.7 ↗
87. 10.1016/j.cell.2014.09.03910.1016/j.cell.2014.09.039 ↗